Viatris is trying to get its two generic versions of semaglutide approved for sale. Novo Nordisk is suing Viatris to prevent the approval from happening.

Viatris reported strong second-quarter earnings, beating estimates on both revenue and earnings per share. The company showed signs of sales growth on a divestiture adjusted basis and is on track f...

Viatris is paying down its debt and planning to return capital to shareholders too. The generic drugmaker's growth hasn't been very impressive so far.